LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Ernegger, Thomas"
  2. AU="Li-Yun Jia"

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel: Octanorm [cutaquig®], a new immunoglobulin (human) subcutaneous 16.5% solution for injection (165 mg/mL) – Biochemical characterization, pathogen safety, and stability

    Gelbmann, Nicola / Zöchling, Alfred / Pichotta, Alexander / Schmidt, Torben / Murányi, Andrej / Ernegger, Thomas / Pock, Katharina / Römisch, Jürgen

    Biologicals. 2019 July, v. 60

    2019  

    Abstract: Octanorm (marketed as cutaquig® in Canada and US [2018] and registered in several European countries [2019]) is a new immunoglobulin subcutaneous 16.5% liquid for the treatment of patients with primary immune deficiency (PID) and secondary immune ... ...

    Abstract Octanorm (marketed as cutaquig® in Canada and US [2018] and registered in several European countries [2019]) is a new immunoglobulin subcutaneous 16.5% liquid for the treatment of patients with primary immune deficiency (PID) and secondary immune deficiency (SID) depending on country's specific indications.Octanorm contains ≥96% human IgG and is characterized by especially low concentrations of polymers and aggregates, IgA and IgM, a physiological osmolality along with a low isoagglutinin titer. The Octanorm manufacturing process is based on the well-established IVIG octagam® 5% and 10% process, but yields a higher immunoglobulin concentration of 16.5% in the final product. Octanorm shows a distribution of immunoglobulin G subclasses closely proportional to native human plasma and comprises a broad spectrum of antibodies against infectious agents. Potential procoagulant activity is not detectable. IgG functionality and physico-chemical integrity have been demonstrated by state-of-the-art-methods.The virus safety of Octanorm is ensured via a combination of three validated independent methods as part of the manufacturing process. Substantial prion depletion during the manufacturing process has also been demonstrated.Compared with other commercially available subcutaneous immunoglobulin (SCIG) 20% products, Octanorm 16.5% shows a lower viscosity, which is a valuable feature that allows for a more comfortable infusion experience.
    Schlagwörter antibodies ; humans ; immunoglobulin A ; immunoglobulin G ; immunoglobulin M ; liquids ; manufacturing ; osmolality ; pathogens ; patients ; polymers ; prions ; viruses ; viscosity
    Sprache Englisch
    Erscheinungsverlauf 2019-07
    Umfang p. 60-67.
    Erscheinungsort Elsevier Ltd
    Dokumenttyp Artikel
    ZDB-ID 1017370-5
    ISSN 1095-8320 ; 1045-1056
    ISSN (online) 1095-8320
    ISSN 1045-1056
    DOI 10.1016/j.biologicals.2019.05.002
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Octanorm [cutaquig®], a new immunoglobulin (human) subcutaneous 16.5% solution for injection (165 mg/mL) - Biochemical characterization, pathogen safety, and stability.

    Gelbmann, Nicola / Zöchling, Alfred / Pichotta, Alexander / Schmidt, Torben / Murányi, Andrej / Ernegger, Thomas / Pock, Katharina / Römisch, Jürgen

    Biologicals : journal of the International Association of Biological Standardization

    2019  Band 60, Seite(n) 60–67

    Abstract: Octanorm (marketed as cutaquig® in Canada and US [2018] and registered in several European countries [2019]) is a new immunoglobulin subcutaneous 16.5% liquid for the treatment of patients with primary immune deficiency (PID) and secondary immune ... ...

    Abstract Octanorm (marketed as cutaquig® in Canada and US [2018] and registered in several European countries [2019]) is a new immunoglobulin subcutaneous 16.5% liquid for the treatment of patients with primary immune deficiency (PID) and secondary immune deficiency (SID) depending on country's specific indications. Octanorm contains ≥96% human IgG and is characterized by especially low concentrations of polymers and aggregates, IgA and IgM, a physiological osmolality along with a low isoagglutinin titer. The Octanorm manufacturing process is based on the well-established IVIG octagam® 5% and 10% process, but yields a higher immunoglobulin concentration of 16.5% in the final product. Octanorm shows a distribution of immunoglobulin G subclasses closely proportional to native human plasma and comprises a broad spectrum of antibodies against infectious agents. Potential procoagulant activity is not detectable. IgG functionality and physico-chemical integrity have been demonstrated by state-of-the-art-methods. The virus safety of Octanorm is ensured via a combination of three validated independent methods as part of the manufacturing process. Substantial prion depletion during the manufacturing process has also been demonstrated. Compared with other commercially available subcutaneous immunoglobulin (SCIG) 20% products, Octanorm 16.5% shows a lower viscosity, which is a valuable feature that allows for a more comfortable infusion experience.
    Mesh-Begriff(e) Adult ; Biomarkers, Pharmacological ; Drug Stability ; Female ; Humans ; Immunoglobulin G/chemistry ; Immunoglobulin G/therapeutic use ; Immunologic Deficiency Syndromes/drug therapy ; Infusions, Subcutaneous
    Chemische Substanzen Biomarkers, Pharmacological ; Immunoglobulin G
    Sprache Englisch
    Erscheinungsdatum 2019-06-01
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 1017370-5
    ISSN 1095-8320 ; 1045-1056
    ISSN (online) 1095-8320
    ISSN 1045-1056
    DOI 10.1016/j.biologicals.2019.05.002
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Biochemical characterization and stability of immune globulin intravenous 10% liquid (Panzyga

    Mersich, Christa / Ahrer, Karin / Buchacher, Andrea / Ernegger, Thomas / Kohla, Guido / Kannicht, Christoph / Pock, Katharina / Römisch, Jürgen

    Biologicals : journal of the International Association of Biological Standardization

    2017  Band 45, Seite(n) 33–38

    Abstract: ... ...

    Abstract Panzyga
    Mesh-Begriff(e) Adult ; Chromatography, High Pressure Liquid ; Clinical Trials, Phase III as Topic ; Cold Temperature ; Drug Stability ; Drug Storage/methods ; Enzyme-Linked Immunosorbent Assay ; Humans ; Immunoglobulin G/chemistry ; Immunoglobulin G/metabolism ; Immunoglobulin G/therapeutic use ; Immunoglobulins, Intravenous/chemistry ; Immunoglobulins, Intravenous/metabolism ; Immunoglobulins, Intravenous/therapeutic use ; Immunologic Deficiency Syndromes/drug therapy ; Oxazines/metabolism ; Protein Binding ; Purpura, Thrombocytopenic, Idiopathic/drug therapy ; Treatment Outcome
    Chemische Substanzen Immunoglobulin G ; Immunoglobulins, Intravenous ; Oxazines ; Panzyga ; nile red (P476F1L81G)
    Sprache Englisch
    Erscheinungsdatum 2017-01
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 1017370-5
    ISSN 1095-8320 ; 1045-1056
    ISSN (online) 1095-8320
    ISSN 1045-1056
    DOI 10.1016/j.biologicals.2016.10.003
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang